Select Clinical Trials Launches New Clinical Trial Search Engine Website
Select Clinical Trials, a public service for all individuals interested in medical research, launched a new website that catalogues leading clinical trials conducted by doctors and healthcare professionals that the public can participate in.
Select Clinical Trials (SCT), a nationwide service that provides clinical trial opportunities for the public, announced today they have launched their premier website. The company designed their website to help identify clinical trials for common illnesses and medical conditions and provide the public with an easy-to-use resource to locate clinical studies.
The SCT website contains a directory of available clinical trials, which allows individuals interested in volunteering as trial participants to search based on doctor, therapeutic area, medical condition or zip code. The site provides detailed information about each clinical trial listed such as eligibility criteria, compensation to participants, location, the name of the coordinator and the name of the principal investigator. Clinical trials target both healthy individuals and people living with a specific medical condition. All clinical trials are open to residents of the United States, with age requirements specific to each trial.
The new website also features a complete listing of doctors and sites who are currently offering clinical trials. Interested volunteers can research information about the clinical trials before deciding whether to participate. They can also view associated clinical trials and areas of expertise.
“Clinical trials are an integral part of medical research,” explained Angela Strong, President and CEO of Select Clinical Trials. “My vision for SCT is twofold: first, to provide information about clinical trials to individuals looking to participate in medical research and secondly, to acknowledge the principal investigators and coordinators who truly excel at what they do.”
With the launch of the website, SCT is also introducing an innovative award program that identifies research sites, principal investigators and coordinators as “Top Performers” in the conduct of clinical research. The Top Performer recognition will help research subjects, sponsors and CROs identify successful research sites, principal investigators and coordinators.
Nominations for the award can be received by anyone who is registered with SCT: consumers, trial participants, sponsors, CROs, principal investigators and coordinators. SCT provides the qualifications for all nominees here: http://selectclinicaltrials.com/award-criteria/. SCT will begin posting the awards in 2015.
For more information on how to advertise clinical trials as a PI, coordinator, sponsor or CRO, visit http://www.selectclinicaltrials.com.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
